Treatment Strategy for Dyslipidemia in Cardiovascular Disease Prevention: Focus on Old and New Drugs
Prevention and treatment of dyslipidemia should be considered as an integral part of individual cardiovascular prevention interventions, which should be addressed primarily to those at higher risk who benefit most. To date, statins remain the first-choice therapy, as they have been shown to reduce t...
Main Authors: | Donatella Zodda, Rosario Giammona, Silvia Schifilliti |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2018-01-01
|
Series: | Pharmacy |
Subjects: | |
Online Access: | http://www.mdpi.com/2226-4787/6/1/10 |
Similar Items
-
Classical and Novel Lipid-Lowering Therapies for Diabetic Patients with Established Coronary Artery Disease or High Risk of Coronary Artery Disease—A Narrative Clinical Review
by: Nikolaos Velidakis, et al.
Published: (2024-04-01) -
Assessment of the global and national market for lipid modifying agents: retrospective and innovation
by: A. V. Lokhmacheva, et al.
Published: (2023-08-01) -
Medical Management of Dyslipidemia for Secondary Stroke Prevention: Narrative Review
by: Yoonkyung Chang, et al.
Published: (2023-04-01) -
Effects of Hypolipidemic Drugs on Psoriasis
by: Mateusz Matwiejuk, et al.
Published: (2023-03-01) -
Long-term effectiveness and safety of lomitapide in patients with homozygous familial hypercholesterolemia: an observational case series
by: Patrizia Suppressa, et al.
Published: (2024-10-01)